Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2011

BMS Taps BAC to Develop Ligands for Adnectin Biotherapeutics

  • BAC inked a collaboration with Bristol-Myers Squibb (BMS) to generate affinity ligands for the purification and analysis of BMS’ Adnectins™ biologics. BAC will work to discover and develop custom ligands on its CaptureSelect platform.

    “Our CaptureSelect platform enables us to produce ligands that have high affinity and specificity for individual proteins and facilitates the generation of an exceptionally pure product in a single purification step,” comments Laurens Sierkstra, CEO of BAC. “We are delighted to collaborate with Bristol-Myers Squibb on the development of ligands for their Adnectin proteins. These custom ligands should simplify the purification process.”

    Derived from human fibronectin, Adnectins are engineered using BMS’ PROfusion™ technology to either block or stimulate the action of specific targets across a range of therapeutic areas. BMS acquired these compounds when it bought Adnexus Therapeutics in October 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »